Nuveen’s Idexx Laboratories IDXX Stock Holding History

Nuveen’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,500	Closed	-$2K	–	3229
2022 Q3	$2K	Buy	+7,500	New	+$2.76M	﹤0.01%	3259

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen's IDXX Position: Q1 2026 in Review

Nuveen reduced its Idexx Laboratories (IDXX) stake by 4.4% in Q1 2026, selling an estimated $13M and leaving 445,804 shares worth $250M. The position accounts for 0.07% of the portfolio, ranked #224.

Nuveen first reported a position in IDXX in Q2 2013 and has held it in 52 quarters since. The position peaked at $396M in Q2 2021. 1,313 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Nuveen held 445,804 shares of Idexx Laboratories worth $250M as of Q1 2026.
Nuveen sold 20,326 Idexx Laboratories shares in Q1 2026, an estimated $13M.
Idexx Laboratories made up 0.07% of Nuveen's portfolio in Q1 2026, its #224 holding.
Nuveen first reported a position in Idexx Laboratories in Q2 2013 and has held it in 52 quarters since.
Nuveen's Idexx Laboratories position peaked at $396M in Q2 2021.
1,313 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.